Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Monday, July 22, 2024STADA and Alvotech have launched Uzpruvo the first approved biosimilar to Stelara in Europe across a majority of European countries This includes the largest markets in the region where pricing and reimbursement approvals
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
Monday, July 22, 2024Mesoblast Limited global leader in allogeneic cellular medicines for inflammatory diseases announced today that the confirmatory Phase trial of its allogeneic immunoselected and industrially manufactured stromal cell product
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable
Saturday, July 20, 2024Bristol Myers Squibb today announced that the European Medicines Agency validated its Type II variation application for Opdivo plus Yervoy as a potential
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Friday, July 19, 2024Synaptogenix Inc an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders today announced a new
Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
Friday, July 19, 2024BIOXYTRAN INC a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID other viral diseases and stroke is pleased to announce a Joint Venture with the Heme Foundation
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
Friday, July 19, 2024Silo Pharma Inc a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments today announced
BioInvent announces new clinical trial collaboration and supply agreement with MSD to evaluate BI-1607 in combination with KEYTRUDA (pembrolizumab) and ipilimumab
Thursday, July 18, 2024BioInvent International AB a biotech company focused on the discovery and development of novel and firstinclass immunemodulatory antibodies for cancer
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
Wednesday, July 17, 2024SELLAS Life Sciences Group Inc a latestage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
Wednesday, July 17, 2024Trethera Corporation a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
Wednesday, July 17, 2024Silo Pharma Inc a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments
